Episodebeskrivelse
Episode 157 — 02 November 2026
HCA signals access erosion in US healthcare; new subcutaneous Leqembi approved; FTC settles with CVS Caremark over insulin pricing; ICER expands scientific advice to pre-Phase 3.
Hosted by Marcus and Sara.
Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.
Full transcript and sources at outcomes-analytica.no/podcast

